Sanofi SA Company Profile (NYSE:SNY)

About Sanofi SA (NYSE:SNY)

Sanofi SA logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NYSE:SNY
  • CUSIP: N/A
  • Web:
  • Market Cap: $123.93 billion
  • Outstanding Shares: 2,525,475,000
Average Prices:
  • 50 Day Moving Avg: $47.02
  • 200 Day Moving Avg: $42.95
  • 52 Week Range: $36.81 - $50.24
  • Trailing P/E Ratio: 24.77
  • Foreward P/E Ratio: 14.82
  • P/E Growth: 1.62
Sales & Book Value:
  • Annual Revenue: $37.86 billion
  • Price / Sales: 3.27
  • Book Value: $24.68 per share
  • Price / Book: 1.99
  • Annual Dividend: $1.12
  • Dividend Yield: 3.2%
  • EBIDTA: $11.31 billion
  • Net Margins: 13.66%
  • Return on Equity: 26.37%
  • Return on Assets: 14.46%
  • Debt-to-Equity Ratio: 0.27%
  • Current Ratio: 1.47%
  • Quick Ratio: 1.00%
  • Average Volume: 1.66 million shs.
  • Beta: 0.98
  • Short Ratio: 3.17

Frequently Asked Questions for Sanofi SA (NYSE:SNY)

What is Sanofi SA's stock symbol?

Sanofi SA trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi SA pay dividends? What is the dividend yield for Sanofi SA?

Sanofi SA announced an annual dividend on Friday, February 17th. Investors of record on Monday, May 15th will be given a dividend of $1.5771 per share on Wednesday, June 7th. This represents a dividend yield of 3.65%. The ex-dividend date of this dividend is Thursday, May 11th. This is an increase from Sanofi SA's previous annual dividend of $1.10. View Sanofi SA's Dividend History.

How were Sanofi SA's earnings last quarter?

Sanofi SA (NYSE:SNY) issued its earnings results on Friday, April, 28th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.73 by $0.03. The company earned $8.65 billion during the quarter, compared to analysts' expectations of $8.40 billion. Sanofi SA had a return on equity of 26.37% and a net margin of 13.66%. The business's revenue for the quarter was up 1.2% compared to the same quarter last year. View Sanofi SA's Earnings History.

Where is Sanofi SA's stock going? Where will Sanofi SA's stock price be in 2017?

14 equities research analysts have issued 12-month price objectives for Sanofi SA's stock. Their forecasts range from $50.00 to $93.00. On average, they expect Sanofi SA's share price to reach $71.50 in the next twelve months. View Analyst Ratings for Sanofi SA.

Who are some of Sanofi SA's key competitors?

Who owns Sanofi SA stock?

Sanofi SA's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Barrow Hanley Mewhinney & Strauss LLC (1.16%), Fisher Asset Management LLC (0.50%), Hotchkis & Wiley Capital Management LLC (0.41%), Boston Partners (0.34%), Bank of America Corp DE (0.30%) and FMR LLC (0.21%). View Institutional Ownership Trends for Sanofi SA.

Who sold Sanofi SA stock? Who is selling Sanofi SA stock?

Sanofi SA's stock was sold by a variety of institutional investors in the last quarter, including Hotchkis & Wiley Capital Management LLC, Morgan Stanley, Baird Financial Group Inc., SG Americas Securities LLC, FMR LLC, Jane Street Group LLC, Boston Partners and Paulson & CO. Inc.. View Insider Buying and Selling for Sanofi SA.

Who bought Sanofi SA stock? Who is buying Sanofi SA stock?

Sanofi SA's stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Global Financial Private Capital LLC, Karp Capital Management Corp, Bank of America Corp DE, Russell Investments Group Ltd., Mondrian Investment Partners LTD, Parametric Portfolio Associates LLC and Hamlin Capital Management LLC. View Insider Buying and Selling for Sanofi SA.

How do I buy Sanofi SA stock?

Shares of Sanofi SA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sanofi SA stock cost?

One share of Sanofi SA stock can currently be purchased for approximately $49.07.

Analyst Ratings

Consensus Ratings for Sanofi SA (NYSE:SNY) (?)
Ratings Breakdown: 2 Sell Ratings, 8 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.14)
Consensus Price Target: $71.50 (45.71% upside)

Analysts' Ratings History for Sanofi SA (NYSE:SNY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Berenberg BankDowngradeBuy -> HoldLowView Rating Details
4/20/2017JPMorgan Chase & Co.Reiterated RatingNeutralMediumView Rating Details
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
4/6/2017ArgusInitiated CoverageBuy -> Buy$50.00LowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
2/9/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017Goldman Sachs Group IncReiterated RatingHoldN/AView Rating Details
11/29/2016Morgan StanleyUpgradeEqual Weight -> OverweightN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralN/AView Rating Details
6/28/2016Citigroup IncReiterated RatingNeutralN/AView Rating Details
5/3/2016Bank of America CorpReiterated RatingBuy$58.00N/AView Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00N/AView Rating Details
12/16/2015Oddo SecuritiesDowngradeReduceN/AView Rating Details
11/9/2015Bryan, Garnier & CoReiterated RatingBuy -> NeutralN/AView Rating Details
9/16/2015Sarasin & PartnersUpgradeBuyN/AView Rating Details
7/13/2015Deutsche Bank AGUpgradeBuyN/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Sanofi SA (NYSE:SNY)
Earnings by Quarter for Sanofi SA (NYSE:SNY)
Earnings History by Quarter for Sanofi SA (NYSE:SNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/28/20173/31/2017$0.73$0.76$8.40 billion$8.65 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.88 billionViewN/AView Earnings Details
10/29/2015Q315$0.88$0.89$10.97 billion$10.67 billionViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.21 billion$9.78 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.34 billion$10.39 billionViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.19 billion$10.82 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.19 billion$10.88 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sanofi SA (NYSE:SNY)
2017 EPS Consensus Estimate: $3.21
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.75$0.78$0.77
Q2 20171$0.74$0.74$0.74
Q3 20171$0.90$0.90$0.90
Q4 20171$0.80$0.80$0.80
(Data provided by Zacks Investment Research)


Current Dividend Information for Sanofi SA (NYSE:SNY)
Next Dividend:6/7/2017
Annual Dividend:$1.12
Dividend Yield:2.28%
Dividend Growth:-2.50% (3 Year Average)
Payout Ratio:54.90% (Trailing 12 Months of Earnings)
36.13% (Based on This Year's Estimates)
33.84% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Sanofi SA (NYSE:SNY)

Dividend History by Quarter for Sanofi SA (NYSE:SNY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Sanofi SA (NYSE:SNY)
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.63%
Insider Trades by Quarter for Sanofi SA (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi SA (NYSE:SNY)
Insider Trades by Quarter for Sanofi SA (NYSE:SNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sanofi SA (NYSE:SNY)
Latest Headlines for Sanofi SA (NYSE:SNY)
DateHeadline logoFDA Approves 1st Drug For GCA, Puma Leaps, Will SBPH Spring A Surprise? - May 23 at 9:14 AM logo​Sanofi Genzyme takes on world’s top-selling drugs with new approval - May 23 at 9:14 AM logoSanofi Wins Favorable CHMP Opinion for Biosimilar Humalog - May 22 at 6:57 PM logoBlog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispro Biosimilar for Treatment of Diabetes Mellitus - May 22 at 8:55 AM logoBull of the Day: Regeneron (REGN) - May 17 at 9:30 AM logoPost Earnings Coverage as Merck's EPS Surged 40%; Raised Outlook - May 15 at 9:14 AM logoHenri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71 - May 14 at 11:28 AM logoBerenberg Bank Downgrades Sanofi SA (SNY) to Hold - May 14 at 8:47 AM logoSanofi : SNY-US: Dividend Analysis : May 15th, 2017 (record date) : By the numbers : May 12, 2017 - May 13 at 12:49 AM logoSanofi SA Target of Unusually High Options Trading (SNY) - May 10 at 5:14 PM logoA giant drugmaker just set the strictest price-increase caps of the industry - May 9 at 10:25 AM logoSanofi pegs U.S. drug price rises to below healthcare inflation - May 9 at 10:25 AM logoSanofi SA (SNY) Receiving Somewhat Favorable News Coverage, Report Shows - May 5 at 11:45 PM logoSanofi SA (SNY) Receives Average Recommendation of "Hold" from Brokerages - May 5 at 2:47 PM logoSanofi SA (SNY) Earning Positive News Coverage, Study Shows - May 2 at 9:12 PM logoSurvey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment - May 2 at 9:21 AM logoSanofi SA (SNY) Posts Earnings Results, Beats Expectations By $0.03 EPS - May 1 at 7:22 PM logoSarepta Therapeutics May Attract Activist Attention - May 1 at 7:08 PM logoSanofi Genzyme Announces Approval of Cerdelga™ (eliglustat capsules) by Health Canada for Rare Genetic Condition - May 1 at 11:43 AM logoSanofi SA (SNY) Given Coverage Optimism Rating of 0.22 - April 29 at 9:57 PM logoSanofi SA (SNY) CEO Olivier Brandicourt on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - April 28 at 4:09 PM logoSanofi Shares Hit 18-Month High As Genzyme and Consumer Goods Deliver Strong Q1 - April 28 at 4:09 PM logoSanofi Delivers Robust Q1 2017 Financial Results - April 28 at 4:09 PM logoSarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal - April 28 at 4:09 PM logoSanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up - April 28 at 4:09 PM logoYes, Sarepta Reported Earnings…But That's Not Why It's Flying Today - April 28 at 4:09 PM logoSanofi beats 1Q profit forecasts - April 28 at 4:09 PM logo​Sarepta shares jump as CEO’s planned exit spurs takeover speculation - April 28 at 4:09 PM logo[$$] Sanofi 1Q Net Profit Rises on Sale of Animal-Health Unit - April 28 at 4:09 PM logoSanofi SA (SNY) Stock Rating Upgraded by TheStreet - April 27 at 3:50 PM logoSanofi SA (SNY) Receives Media Impact Score of 0.12 - April 26 at 8:06 PM logoOne in 7 people in Nevada is living with diabetes, and the state is now pushing a new approach to tackle the cost of treatment - April 26 at 4:20 PM logoMoody's: Outlook for global pharmaceuticals industry stable on low earnings growth, new product launches - April 26 at 9:17 AM logoSanofi SA (SNY) Cut to "Hold" at Zacks Investment Research - April 25 at 1:38 PM logoRegeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection - April 25 at 9:45 AM logoNew Investigational Data on Six-Year Efficacy of Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented at AAN - April 25 at 9:45 AM logoSanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection - April 25 at 9:45 AM logoNew Data Suggest Positive Effects of Sanofi Genzyme’s Aubagio® (teriflunomide) on Cortical Gray Matter Atrophy - April 25 at 9:45 AM logoK-Mart to Sell Cheaper EpiPen Alternative at a Third of the Cost - April 25 at 9:45 AM logoRegeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis - April 24 at 11:27 AM logoSanofi Receives FDA Approval of Thymoglobulin® for the Prevention of Acute Kidney Transplant Rejection - April 24 at 11:27 AM logoSanofi files U.S. antitrust lawsuit against Mylan over EpiPen - April 24 at 11:27 AM logoBrokers Issue Forecasts for Sanofi SA's Q1 2017 Earnings (SNY) - April 24 at 7:14 AM logoSomewhat Negative Media Coverage Extremely Likely to Impact Sanofi SA (SNY) Share Price - April 23 at 9:05 AM logoSanofi Genzyme hit with patent lawsuit over new eczema drug - April 20 at 8:06 AM logoSanofi says could buy device assets to boost diabetes - April 20 at 8:06 AM logoSanofi SA (SNY) Receives Neutral Rating from JPMorgan Chase & Co. - April 20 at 7:21 AM logo[$$] Actis-backed MediS Group Acquires Winthrop Pharma Senegal - April 19 at 9:09 AM logoSanofi SA (SNY) Earning Very Positive Press Coverage, Analysis Finds - April 17 at 10:24 AM logoZacks Investment Research Upgrades Sanofi SA (SNY) to Buy - April 17 at 8:04 AM



Sanofi SA (SNY) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff